Abstract 2701: Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Predicts Lack of Functional Recovery in Patients with New Onset Heart Failure Undergoing Optimal Therapy

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Rafael Romaguera ◽  
Mercedes Nadal-Barangé ◽  
Jordi Estornell ◽  
Victoria Jacas ◽  
Leandro Perez-Bosca ◽  
...  

Background : Some patients with heart failure may have a marked improvement in left ventricular function (LVF) even in the absence of optimized drug therapy. Previous data shows that the proportion of patients matching the criteria for device implantation dropped significantly after 6 months on optimal medial therapy. However the predictors of recovery in LVF are not well understood. Objetive : We evaluated the feasibility of using late gadolinium enhancemnet cardiovascular magnetic resonance (LGE-CMR) to predict the improvement in LVF in new onset heart failure (AHF) patients on optimized medical therapy. Methods : Seventy six patients admitted with AHF and EF < 35% underwent LGE-CMR. Baseline and follow-up echocardiography was performed to assess functional recovery. We evaluated change in the proportion of patients who satisfied criteria for device implantation (EF< 35%) after 7 month on optimal therapy. Results : During follow-up 81% were treated with B-Blockers, 91% with ACEI and 33% with spironolactone. Twenty two patients (29%) had late gadolinium enhancement. Change in LVF was significantly hgher in patients who did not show LGE-CMR (p< 0.006). Al follo-up 55% of patients not satisfied criteria for device implantation as they developed functional recovery. Multvariate analysis showed that LGE-CMR (OR 0.10, CI 0.02–0.48, p =0.004), left bundle branch block (OR 0.14 CI 0.03–0.70, p=0.0017) and betablockers (OR 5.94 CI 1.12–31.40, p=0.006) were indepent predictors of functional recovery. Conclusions : The proportion of patients with AHF who satisfied criteria for device implantation as a primary prevention, dropped signifcantly after 7 months on optimal medial treatment. Late gadolinium enhancement CMR is a useful tool to identify these patients

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Angel T. Chan ◽  
William Dinsfriend ◽  
Jiwon Kim ◽  
Brian Yum ◽  
Razia Sultana ◽  
...  

Abstract Background Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) is widely used to identify cardiac neoplasms, for which diagnosis is predicated on enhancement stemming from lesion vascularity: Impact of contrast-enhancement pattern on clinical outcomes is unknown. The objective of this study was to determine whether cardiac metastasis (CMET) enhancement pattern on LGE-CMR impacts prognosis, with focus on heterogeneous lesion enhancement as a marker of tumor avascularity. Methods Advanced (stage IV) systemic cancer patients with and without CMET matched (1:1) by cancer etiology underwent a standardized CMR protocol. CMET was identified via established LGE-CMR criteria based on lesion enhancement; enhancement pattern was further classified as heterogeneous (enhancing and non-enhancing components) or diffuse and assessed via quantitative (contrast-to-noise ratio (CNR); signal-to-noise ratio (SNR)) analyses. Embolic events and mortality were tested in relation to lesion location and contrast-enhancement pattern. Results 224 patients were studied, including 112 patients with CMET and unaffected (CMET -) controls matched for systemic cancer etiology/stage. CMET enhancement pattern varied (53% heterogeneous, 47% diffuse). Quantitative analyses were consistent with lesion classification; CNR was higher and SNR lower in heterogeneously enhancing CMET (p < 0.001)—paralleled by larger size based on linear dimensions (p < 0.05). Contrast-enhancement pattern did not vary based on lesion location (p = NS). Embolic events were similar between patients with diffuse and heterogeneous lesions (p = NS) but varied by location: Patients with right-sided lesions had threefold more pulmonary emboli (20% vs. 6%, p = 0.02); those with left-sided lesions had lower rates equivalent to controls (4% vs. 5%, p = 1.00). Mortality was higher among patients with CMET (hazard ratio [HR] = 1.64 [CI 1.17–2.29], p = 0.004) compared to controls, but varied by contrast-enhancement pattern: Diffusely enhancing CMET had equivalent mortality to controls (p = 0.21) whereas prognosis was worse with heterogeneous CMET (p = 0.005) and more strongly predicted by heterogeneous enhancement (HR = 1.97 [CI 1.23–3.15], p = 0.005) than lesion size (HR = 1.11 per 10 cm [CI 0.53–2.33], p = 0.79). Conclusions Contrast-enhancement pattern and location of CMET on CMR impacts prognosis. Embolic events vary by CMET location, with likelihood of PE greatest with right-sided lesions. Heterogeneous enhancement—a marker of tumor avascularity on LGE-CMR—is a novel marker of increased mortality risk.


Sign in / Sign up

Export Citation Format

Share Document